Log in

OHR Pharmaceutical Stock Forecast, Price & News

-0.20 (-2.56 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $7.60
50-Day Range
MA: $8.21
52-Week Range
Now: $7.60
Volume210,549 shs
Average Volume180,228 shs
Market Capitalization$21.50 million
P/E RatioN/A
Dividend YieldN/A
OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Read More
OHR Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:OHRP



Sales & Book Value

Annual SalesN/A
Book Value$3.86 per share


Net Income$-13,230,000.00


Market Cap$21.50 million
Next Earnings DateN/A
-0.20 (-2.56 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OHRP News and Ratings via Email

Sign-up to receive the latest news and ratings for OHRP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions

How has OHR Pharmaceutical's stock been impacted by Coronavirus (COVID-19)?

OHR Pharmaceutical's stock was trading at $7.18 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OHRP shares have increased by 5.8% and is now trading at $7.60.
View which stocks have been most impacted by COVID-19

How were OHR Pharmaceutical's earnings last quarter?

OHR Pharmaceutical Inc (NASDAQ:OHRP) released its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter.
View OHR Pharmaceutical's earnings history

When did OHR Pharmaceutical's stock split? How did OHR Pharmaceutical's stock split work?

OHR Pharmaceutical's stock reverse split before market open on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 1st 2019. An investor that had 100 shares of OHR Pharmaceutical stock prior to the reverse split would have 5 shares after the split.

Who are some of OHR Pharmaceutical's key competitors?

What other stocks do shareholders of OHR Pharmaceutical own?

Who are OHR Pharmaceutical's key executives?

OHR Pharmaceutical's management team includes the following people:
  • Dr. Jason Scott Slakter, CEO, Pres & Director (Age 61)
  • Mr. Samuel Backenroth, CFO, VP of Bus. Devel. & Sec. (Age 35)
  • Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 55)
  • Dr. Marlene Modi, Head of Preclinical & Regulatory Affairs

What is OHR Pharmaceutical's stock symbol?

OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."

How do I buy shares of OHR Pharmaceutical?

Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OHR Pharmaceutical's stock price today?

One share of OHRP stock can currently be purchased for approximately $7.60.

How big of a company is OHR Pharmaceutical?

OHR Pharmaceutical has a market capitalization of $21.50 million. OHR Pharmaceutical employs 3 workers across the globe.

What is OHR Pharmaceutical's official website?

The official website for OHR Pharmaceutical is www.ohrpharmaceutical.com.

How can I contact OHR Pharmaceutical?

OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.